Next Catalyst, page-15

Another good article on IMC

https://www.nextbiotech.com.au/blockbuster-results-imcs-nash-liver-therapy-trials/

Please refer to the link for the full article.  These are some of the important bits.
Beyond NASH, what are the possibilities for IMM-124E’s anti-LPS effects?

Just to further state the case, LPS has implications reaching far beyond NASH treatments.
In fact, a growing body of literature is proving that LPS has effects on a huge number of diseases, which means a dramatically increased scope of potential applications for any safe and effective anti-LPS treatment, particularly one as easily administered as IMM-124E (it is the world’s first oral LPS antagonist).
The low level inflammation in the body caused by a high level of LPS has been associated with a laundry list of chronic illnesses including:

• Alzheimer’s disease

• Diabetes

• Obesity

• Cardiovascular disease

• Chronic fatigue syndrome

• Cancer

• Inflammatory bowel disease

• Infertility

• Autism

• Depression

• Schizophrenia

It’s difficult to even imagine the money changing hands across all of those treatment areas.
There’s a mind-bogglingly large market to tap into if you can deliver a safe, easy to administer, and proven treatment option that can assist even half of the conditions listed above … a fact that won’t be lost on Big Pharma companies.
What’s more, when you have a platform underpinning your ground-breaking treatment, and that platform can produce seemingly endless treatment options… what’s there to do but prepare for lift-off?



One of the most undervalued bio tech company on the ASX!  This will take off once the new shares are issued.  The US investment houses will not settle for a 10% or 20% return